Suppr超能文献

益生菌通过调节NLRP3炎性小体来调控炎症:一种针对COVID-19的潜在治疗方法

Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19.

作者信息

Kasti Arezina N, Synodinou Kalliopi D, Pyrousis Ioannis A, Nikolaki Maroulla D, Triantafyllou Konstantinos D

机构信息

Department of Nutrition and Dietetics, Attikon University General Hospital, 12462 Athens, Greece.

Medical School, University of Patras, 26504 Patras, Greece.

出版信息

Microorganisms. 2021 Nov 17;9(11):2376. doi: 10.3390/microorganisms9112376.

Abstract

Inflammasomes are cytoplasmic multiprotein complexes formed by the host's immune system as a response to microbial infection and cellular damage. Many studies have revealed various regulators of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome activation, while it has been recently shown that NLRP3 is implicated in COVID-19 pathogenesis. At the same time, probiotics counteract the inflammatory process and modulate cytokine release, thus influencing both innate and adaptive immune systems. Herein, we review the immunomodulatory potential of probiotics on the assembly of NLRP3 inflammasome, as well as the pathophysiological mechanisms supporting the use of probiotic bacteria for SARS-CoV-2 infection management, presenting evidence from preclinical studies of the last decade: in vivo, ex vivo, and mixed trials. Data show that probiotics intake is related to NLRP3 inflammasome attenuation and lower levels of inflammation markers, highlighting the beneficial effects of probiotics on inflammatory conditions. Currently, none of the ongoing clinical trials evaluating the effectiveness of probiotics intake in humans with COVID-19 has been completed. However, evidence from preclinical studies indicates that probiotics may block virus invasion and replication through their metabolites, bacteriocins, and their ability to block Angiotensin-Converting Enzyme 2 (ACE2), and by stimulating the immune response through NLRP3 inflammasome regulation. In this review, the beneficial effects of probiotics in the inflammatory process through NLRP3 inflammasome attenuation are presented. Furthermore, probiotics may target SARS-CoV-2 both by blocking virus invasion and replication and by stimulating the immune response through NLRP3 inflammasome regulation. Heterogeneity of the results-due to, among others, different bacterial strains and their metabolites, forms, dosage, and experimental designs-indicates the need for more extensive research.

摘要

炎性小体是宿主免疫系统在应对微生物感染和细胞损伤时形成的细胞质多蛋白复合物。许多研究揭示了含核苷酸结合寡聚化结构域、富含亮氨酸重复序列和吡啉结构域的蛋白3(NLRP3)炎性小体激活的各种调节因子,而最近有研究表明NLRP3与2019冠状病毒病(COVID-19)的发病机制有关。同时,益生菌可对抗炎症过程并调节细胞因子释放,从而影响先天和适应性免疫系统。在此,我们综述了益生菌对NLRP3炎性小体组装的免疫调节潜力,以及支持使用益生菌治疗严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的病理生理机制,并展示过去十年临床前研究(体内、体外和混合试验)的证据。数据表明,摄入益生菌与NLRP3炎性小体减弱及炎症标志物水平降低有关,突出了益生菌对炎症状态的有益作用。目前,尚无正在进行的评估摄入益生菌对COVID-19患者有效性的临床试验完成。然而,临床前研究的证据表明,益生菌可能通过其代谢产物、细菌素以及阻断血管紧张素转换酶2(ACE2)的能力来阻断病毒入侵和复制,并通过调节NLRP3炎性小体刺激免疫反应。在本综述中,介绍了益生菌通过减弱NLRP3炎性小体在炎症过程中的有益作用。此外,益生菌可能通过阻断病毒入侵和复制以及通过调节NLRP3炎性小体刺激免疫反应来靶向SARS-CoV-2。结果的异质性(尤其是由于不同的细菌菌株及其代谢产物、形式、剂量和实验设计)表明需要进行更广泛的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b958/8624812/43a318406e05/microorganisms-09-02376-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验